Abstract 173P
Background
In the phase III RESORCE trial, regorafenib improved overall survival (OS) vs placebo in pts with uHCC who progressed on sorafenib. The international, prospective REFINE study was designed to evaluate regorafenib in pts with uHCC in routine practice. We present interim results for pts enrolled in REFINE in Korea, China, and Taiwan.
Methods
REFINE is an ongoing observational study that recruited patients with uHCC for whom a decision to treat with regorafenib was made by the treating physician prior to enrollment according to the local health authority approved label. A planned interim analysis was performed when the first 500 pts in the global cohort had been observed for ≥4 months. The primary aim is to assess treatment-emergent adverse events (TEAEs; NCI-CTCAE v4.03). Secondary endpoints include OS, progression-free survival, and tumor response. Tumor response and progression are assessed per investigator according to local standard.
Results
In the interim analysis, a total of 182 pts were enrolled from Korea (n=127; 70%), China (n=48; 26%), and Taiwan (n=7; 4%). The median age was 60 years (range 21–90); 80% were male. At study entry, proportions of pts with ECOG performance status 0/1/≥2 were 37%/49%/5%; proportions with Child–Pugh A/B/C class were 70%/5%/1% (missing/not evaluable: 24%). The initial daily regorafenib dose was 160 mg in 70% of pts and 120 mg/80 mg in 14%/15%; 1 pt started at 40 mg. The mean initial daily dose was 142 mg (standard deviation 31). Median treatment duration was 3.2 months (interquartile range 1.9–9.3). The most frequent TEAEs (reported in ≥5% patients) are shown in the table. Effectiveness results will be presented.
Conclusions
In this interim analysis of pts from Asia in the observational REFINE study, the TEAEs reported were consistent with those reported in the phase III RESORCE trial, although incidence rates of some TEAEs were lower than in RESORCE Table: 173P
TEAE, % | Regorafenib (n=182) | ||
Any grade | Grade 3 | Grade 4 | |
Hand–foot skin reaction | 29 | 1 | - |
Diarrhea | 14 | 2 | 0 |
Decreased appetite | 9 | 1 | 0 |
Abdominal pain | 7 | 3 | 0 |
Hypertension | 6 | 2 | 0 |
Fatigue | 5 | 1 | - |
Clinical trial identification
NCT03289273.
Editorial acknowledgement
Editorial assistance in the writing of this abstract was provided by Jennifer Tobin of OPEN Health Medical Communications (Choice), with financial support from Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
H.Y. Lim: Advisory/Consultancy: Bayer; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Eisai; Advisory/Consultancy: Ono Pharmaceutical. Y.J. Kim: Honoraria (self): Eisai; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (self): BTG; Honoraria (self): Bayer; Honoraria (self): MSD; Honoraria (self), Advisory/Consultancy, Resarch grant/Funding (self): Gilead Sciences; Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Roche. Y-H. Huang: Advisory/Consultancy: Gilead Sciences; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Bayer. C-H. Hsu: Honoraria (self), Advisory/Consultancy: Bristol-Meyers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ono Pharmaceutical; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Lilly; Advisory/Consultancy: Genentech; Advisory/Consultancy: Merck Serono. H.C. Lee: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Bayer; Research grant/Funding (self): Roche; Research grant/Funding (self): Merck; Research grant/Funding (self): Bristol-Myers Squibb. S. Fiala-Buskies: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bayer. S. Kapur: Full/Part-time employment: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session